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preference of physicians in prescribing Oral Antidiabetic Treatments (OATs) versus 
Insulin in Diabetes patients. METHODS: A survey was conducted by CSD, face to 
face interviews with 200 physicians of several specialties, GPs, diabetologists, endo-
crinologists who treat at least 30 diabetic patients/month. The sample emerged from 
four capital cities of Greece. The sampling method was based on stratiﬁed random 
sample. Interviews were conducted from May 12 to June 3, 2009. Results were 
weighted according to the actual distribution of specialties. RESULTS: The number 
of patients with type-1 diabetes is approximately 12% and 88% with type-1 diabetes. 
In DT1 100% patients receive insulin, contrary to DT2 where patients receive 23% 
insulin and 83% OATs. Overall, 60% of T2D patients are regulated. Also when 
adding a third OAT drug 54% of the patients will delay the use of insulin. Unmet 
needs mentioned spontaneously by physicians are: a) poor compliance to treatment; 
b) poor compliance to diet; and c) high cost of co-payment for medicines. CONCLU-
SIONS: Based on the results of the present study, physicians use insulins for DTI 
patients and they prefer OATs for TIID. The economic burden of TIID patients is 
heavy due to high co-payment rate, which might be linked to poorly regulated patients 
leading to higher incidence of diabetes-related complications.
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OBJECTIVES: The specialist outpatient clinics (SOCs) of the 3 acute hospitals of the 
National Healthcare Group (NHG) in Singapore treat over 11,000 patients with dia-
betes mellitus. This paper studies the glycaemic and cholesterol control of type 2 dia-
betes mellitus (T2DM) patients at these SOCs. METHODS: This study included all 
patients with T2DM who attended the hospital SOCs in Jan 2009 for treatment of 
diabetes. These patients had been on follow-up at the same clinic for at least 12 months. 
The latest glycated haemoglobin (HbA1c) and LDL-cholesterol (LDL-c) results were 
compared by age, gender and ethnic group. Data was extracted from the NHG Diabetes 
Registry (CDMS). RESULTS: There were 3,420 T2DM patients with more females 
(53%) and disproportionately more Indians (14.1%) and fewer Chinese (66.3%) than 
the general population. The mean ages of male and female were 61.8 and 64.9 years 
respectively. The proportion of patients with “optimal” HbA1c (a7%) and LDL-c 
(2.6 mmol/L) control increased with age. For HbA1c, 13% of patients 35 years had 
“optimal” control (mean 8.96%, 95%CI 8.42–9.50%) increasing to 61% for patients 
85 years (mean 7.04%, 95%CI 6.79–7.28%). Similarly for LDL-c, 41% of patients 
35 years had “optimal” control (mean 2.92 mmol/L, 95%CI 2.63–3.21 mmol/L), 
increasing to 74% for patients 85 years (mean 2.28 mmol/L, 95%CI 2.14–2.41 mmol/L). 
Chinese had better HbA1c and LDL-c control whilst Malay and Indian were poorest 
for LDL-c and HbA1c respectively. There was no gender difference. CONCLUSIONS: 
The control of HbA1c and LDL-c among T2DM patients improved with age. Younger 
patients and the Malay and Indian subgroups had greater potential to achieve 
“optimal” glycaemic and cholesterol control and reduce the risk of developing 
micro- and macro-vascular complications over time. While the older patients achieved 
better HbA1c control than younger ones, clinicians should remain mindful of side-
effects such as hypoglycaemia among those with very tight glycaemic control.
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OBJECTIVES: This study was conducted to estimate quality adjusted life years 
(QALYs) loss due to diabetes in type 2 diabetic patients of South Korea. METHODS: 
In order to obtain QALYs loss due to morbidity of type 2 diabetes (T2D), we ﬁrstly 
estimated utility weight difference between T2D patients and non-diabetic subjects by 
sex and age groups. We consecutively recruited T2D patients aged 20 or over who 
visited three university hospitals in Seoul and Ilsan from October 2007 to January 
2008 and non-diabetic subjects who took a medical examination from June 2008 to 
Jan 2009 in same hospitals. Utility weight differences on sex and age groups were 
calculated using the EuroQoL EQ-5D and Korean valuation set, and then QALY losses 
was estimated using the utilities and the number of T2D patients in 2003 reported by 
the Korean Diabetes Basic Statistics Study. QALY losses due to T2D mortality corre-
sponded to life expectancy of the death caused T2D from the life table and the Korean 
Death Certiﬁcate in 2003 multiplied by utility weights of healthy people by sex and 
age groups from the 3rd Korea National Health and Nutrition Examination Survey 
(2005). We considered a discount rate as 5%. RESULTS: Total 1,072 T2D patients 
and 387 non-diabetic subjects participated in this survey. Maximum difference 
between T2D patients and non-diabetic subjects was 0.0418 and minimum difference 
was 0.0095 by subgroups. QALY loss estimates due to T2D morbidity were about 
35,125 QALYs in male and 50,613 QALYs in female. Preterm death caused by T2D 
brought about 58,186 QALYs in male and 49,432 QALYs in female considering the 
discount rate. Therefore, total QALY loss was estimated as 193,356 QALYs annually. 
CONCLUSIONS: The results suggest that QALY loss estimates caused by T2D was 
4.0 QALYs/1000 persons in South Korea at 2003.
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OBJECTIVES: To map factors that inﬂuence HTA-agencies in their Health Technol-
ogy Assessments (HTA) on type 2-diabetes agents in the UK (NICE), Scotland (SMC), 
The Netherlands (CVZ) Germany (IQWIG) and Sweden (TLV). METHODS: To 
retrieve the HTA reports, a search was executed using the agencies websites with the 
following keywords: pioglitazone, rosiglitazone, sitagliptin, vildagliptin, exenatide, 
glargine, detemir, aspart, glulisine and lispro. If a report contained several drugs each 
drug was counted separately although a decision could involve a class of drugs. Deci-
sion parameters were clustered in three categories: efﬁcacy, safety and health econom-
ics where each assessment could contain multiple parameters. Overall recommendation 
was classiﬁed in three categories: recommended restricted recommended and not 
recommended in relation to indication based on marketing authorisation. RESULTS: 
35 reports were identiﬁed with 49 assessments. Twelve assessments lead to recom-
mendation (24%), 23 to restricted recommendation (47%) and fourteen to no recom-
mendation (29%). Reasons for recommending a treatment contained in 83% of cases 
one or more arguments related to efﬁcacy, 33% to safety, and 66% to health economic 
aspects of drugs. Reasons for restricted recommendation were 70%, 39%, and 60%, 
and for not recommended were 100%, 57% and 21% respectively. Within each deci-
sion parameter the most common reason for restricting the market authorization 
indication was related to the drug not being cost-effective (57%). The most common 
reason for not recommending a drug was lack of long term data on efﬁcacy (86%). 
CONCLUSIONS: Despite that large variations in results between agencies were 
observed, data demonstrating efﬁcacy of the drug appeared to be the most important 
factor in getting a recommendation for type 2 diabetes treatment. A high incremental 
cost-effectiveness ratio was likely to lead to restrictions in indication (NICE, SMC and 
TLV) whereas lack of long term data could lead to the drug not being recommended 
(IQWIG and CVZ).
PDB74
ETHICAL DILEMMAS OF PHARMACOLOGICAL TREATMENT AND SELF 
MANAGEMENT OF DIABETES—A REVIEW OF THE LITERATURE
Jensen RCØ1, Kaas C2, Mondher T3, Hemels M4
1Novo Nordisk A/S, Bagsværd, Denmark, 2Copenhagen University, Copenhagen, Denmark, 
3University Claude Bernard Lyon, Lyon, France, 4Novo Nordisk A/S, bagsværd, Denmark
OBJECTIVES: There is increasing focus on the ethical analysis in Health Technology 
Assessments (HTA). Due to the escalating epidemic of diabetes, diabetes has become 
an urgent health concern. We therefore systematically reviewed published articles 
describing the ethical aspects of pharmacological treatment and self management 
of diabetes. METHODS: PubMed was searched from inception to 2009 using the 
following combinations of keywords: ethics AND diabetes NOT screening NOT 
transplant. Articles were initially screened for relevance by reading title and abstract. 
If deemed appropriate, by two independent reviewers, full copies of the remaining 
articles were retrieved for further review. RESULTS: Out of 336 articles, only six 
studies were deemed appropriate. The main reason for this high level of rejected arti-
cles was that the majority of identiﬁed articles commented on the ethical approval in 
connection to conducting clinical studies rather than on the ethical aspects of imple-
menting and using the speciﬁc technology. One study described the ethical concern 
related to the costly late complications of diabetes compared to preventing late com-
plications by prescribing and reimbursing insulin. Other ethical issues concerned 
self management and the transferral of responsibility from physician to patient and 
the patient’s capabilities for self management. For people with impaired glucose toler-
ance there were also ethical issues related to initiating a preventive pharmacological 
treatment of the “otherwise well”. Lastly, there is an ethical issue between the norma-
tive gold standard for a healthy and moral lifestyle and a culture of self that values 
authenticity and originality. CONCLUSIONS: Due to the escalating prevalence 
of diabetes and emphasis on ethical analysis in HTAs, both payers and the industry 
needs to get a better understanding of the ethical aspects of self management and 
pharmacological treatment of diabetes. More research should be allocated towards 
investigating the ethical aspects of self management and pharmacological treatment 
of diabetes.
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OBJECTIVES: To compare Health Technology Assessments (HTAs) and reimburse-
ment decisions of a novel antidiabetic drug class, by health care agencies worldwide. 
METHODS: We conducted manual searches of 54 health care agencies’ web sites 
from January 2008 to May 2009. HTAs regarding diabetes were collected and each 
was assessed for date, type (e.g., single drug versus class review) and scope (e.g., 
medicine name). Using a standardized set of categorical criteria, we investigated rec-
ommendations, as well as presence of supporting evidence (e.g., reported outcome 
measures, information sources, and key decision drivers). RESULTS: A total of 21 
completed diabetes assessments were assessed. Data were retrieved from 9 agencies in 
9 countries. The agencies published 21 assessments on diabetes during the review 
period; including 4 clinical guidelines, 9 single drug appraisals and 8 class reviews. Of 
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the 6 agencies (9 publications) that evaluated DPP-4 inhibitors, 2 recommended the 
drug not be listed or funded (CADTH, AHTAPol) and 4 recommended restricted use 
(PBAC, SMC, CVZ and NICE). The most common reason for agency’s disinclination 
for listing/funding was insufﬁcient information on the effectiveness and cost-effective-
ness in the speciﬁed patient population. There are more than 100 HTAs ongoing in 
the endocrine nutritional and metabolic therapeutic area, approximately half of them 
(49 projects) concern diabetes, 21 of which evaluate pharmacological treatment of 
diabetes (8 countries, 11 agencies). CONCLUSIONS: Diabetes prevalence is on the 
rise, attracting increasing attention from health care agencies. Despite using similar 
data sources variable outcomes suggest to us that agencies are applying different 
weightings in their assessment process. The apparent failure to demonstrate effective-
ness in speciﬁed populations suggests late segmentation by manufacturers and insufﬁ-
cient resourcing to generate data. This is often due to late payer requests for such 
analyses motivated by ﬁnancial considerations. Early segmentation and engagement 
with payers is thus critical for HTA success.
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OBJECTIVES: Health Technology Assessment (HTA) is mostly known for its health 
economic properties even though it is a multidisciplinary form of policy research 
examining short- and long-term consequences of the application of a health technol-
ogy. There is an increased focus on ethical analyses in HTA. A descriptive analysis 
was conducted on diabetes HTA reports describing ethical analyses. METHODS: The 
NHS Centre for Reviews and Dissemination HTA database (http://www.crd.york.
ac.uk/crdweb/) was searched (1991–2009) using the keyword ‘diabet*’. HTA reports 
in English language assessing diabetes treatments were included and screened for any 
type of ethical analyses. RESULTS: Of 263 HTA reports identiﬁed in the initial search, 
60 met the inclusion criteria. 4 reports included a type of ethical analysis (2 from 
CADTH, Canada; 1 from AHTA, Australia and 1 from NZHTA, New Zealand). 
CADHT conducted ethical analyses on short- and long-acting insulin analogues 
respectively, concluding that both types of insulin analogues did not exacerbate—
might even better—the psychosocial issues of diabetes, however more quality-of-life        
evidence were needed. In AHTA’s assessment of a continuous glucose monitoring 
device they described equity and access issues related to costs, and that the device 
could not replace standard of care, but should be used as an adjunct. NZHTA’s 
assessment of continuous glucose monitoring devices was also related to equity con-
cerns, concluding a need for more affordable devices. CONCLUSIONS: Ethical analy-
ses are sparse in diabetes, despite stated objectives of best practice and HTA deﬁnitions. 
In the identiﬁed cases, ethical analyses were targeted to meet patients’ needs as well 
as a tool to restrict access for the purpose of fair distribution in government funded 
health care systems. Further research on the methods of ethical analyses is warranted 
as well as the formulation of guidelines to fully estimate the value and ensure an 
optimal role for ethical analyses in HTA.
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OBJECTIVES: The ongoing Cardiovascular (CV) Risk Evaluation in people with 
Type-2 diabetes mellitus (T2DM) on Insulin Therapy (CREDIT) study is assessing the 
effect of insulin on the risk of vascular events. METHODS: CREDIT is a 4-year, 314 
centre, non-interventional trial in North America, Europe and Asia, and includes 3031 
people with T2DM who recently started basal and/or short-acting insulin, premix 
insulin or another insulin type. This analysis examines and compares the characteris-
tics between groups starting basal (n  1563), basal  short-acting (n  444), short-
acting (n  221), premixed (n  700) or another (n  103) insulin. RESULTS: 
Demographic and diabetes characteristics were reasonably balanced between the 
insulin groups, although those receiving basal plus short-acting insulin or premix had 
a trend to higher baseline HbA1c levels vs other insulin types (basal, 9.2 o 1.8%; basal 
 short-acting, 10.1 o 2.2%; short-acting, 9.4 o 2.0%; premix, 9.9 o 2.0%; other, 9.1 
o 2.0%). While the majority had previously used oral glucose lowering drugs (OGLDs) 
(basal, 97%; basal  short-acting, 83%; short-acting, 83%; premix, 94%; other, 
85%), differences in the numbers continuing OGLDs when beginning insulin were 
found. Continued use of OGLDs was highest wth basal insulin (89%) versus the other 
insulins (basal  short-acting, 36%; short-acting, 45%; premix, 62%; other, 34%). 
However, the distribution of types of OGLD used before insulin was similar between 
the groups. There are no clear patterns in CV risk proﬁle by insulin type. Previous 
diagnosis of hypertension (basal, 71%; basal  short-acting, 65%; short-acting, 57%; 
premix, 69%; other, 72%), family history of CV disease (basal, 29%; basal  short-
acting, 25%; short-acting, 21%; premix, 23%; other, 14%) and body mass index 
tended to be lower in the short-acting insulin group. However, triglyceride levels were 
lower in the short-acting and ‘other’ insulin groups vs premix, basal and basal 
plus short-acting groups. CONCLUSIONS: People starting different insulins have 
somewhat different clinical characteristics, which may confound attempts to compare 
future vascular outcomes between regimens.
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OBJECTIVES: Maintaining long-term glycaemic control with insulin therapy can 
reduce the risk of vascular events associated with Type-2 diabetes mellitus (T2DM). 
The Cardiovascular (CV) Risk Evaluation in people with T2DM on Insulin Therapy 
(CREDIT) study is an ongoing 4-year, noninterventional trial in 314 centres across 
North America, Europe and Asia. METHODS: People with T2DM who recently 
started insulin were included. Here we report variation in baseline characteristics of 
participants in eastern vs northern vs southern Europe. RESULTS: Marked differences 
in participant characteristics were found between eastern Europe (n  735), northern 
(n  460) and southern Europe (n  647), including proportion of males (25 vs. 61 
vs. 56%), diabetes duration (8 o 5 vs. 9 o 6 vs. 13 o 9 years), age (58 o 8 vs. 63 o 
11 vs. 63 o 11 years) and HbA1c (9.7 o 1.9 vs. 9.1 o 2.0 vs. 9.3 o 1.9%). Combina-
tions of oral glucose-lowering drugs were common before insulin; sulfonylureas were 
dominant in eastern Europe and metformin elsewhere. Over 80% were taking non-
glucose medications before insulin initiation, most commonly ARBs. People in eastern 
Europe had a greater family history of CV disease, were less physically active, but 
were not more obese (BMI: 30.7 o 5.4 vs. 31.5 o 6.3 vs. 29.6 o 5.9 kg/m2). Rates of 
hypertension were lowest in southern Europe. HDL cholesterol in males was lowest 
in northern Europe and in females was highest in eastern Europe. LDL cholesterol 
was highest in southern Europe. Total cholesterol levels were lowest, but triglyceride 
levels were highest in northern Europe. Smoking was less prevalent in eastern Europe. 
Most people began with a basal insulin regimen (60 vs 63 vs. 62%); more people used 
meal-time insulin in eastern Europe (19 vs. 11 vs. 17%) and pre-mixes in northern 
Europe (22 vs. 28 vs. 13%). CONCLUSIONS: Baseline characteristics of people start-
ing insulin reveals some striking differences between European regions; how these 
translate into CV events as the study progresses will be of interest.
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OBJECTIVES: The Cardiovascular Risk Evaluation in people with Type-2 diabetes 
mellitus (T2DM) on Insulin Therapy (CREDIT) study is evaluating the effect of insulin 
on the risk of vascular events, which can be reduced via long-term glycaemic control. 
METHODS: CREDIT is a 4-year, 314 centre, non-interventional trial in North 
America, Europe and Asia. It includes 3031 people with T2DM who had recently 
started basal, short-acting or premix insulin, over half of whom received basal insulin 
alone (n  1563). This analysis examines the baseline characteristics amongst the 
subgroup initiating basal insulin after oral failure and compares them with those of 
the wider CREDIT population. RESULTS: The mean starting dose of basal insulin 
was 14.7 IU/day, administered once daily in 86% of participants. Of these, 61% took 
their injection at bedtime, 21% at breakfast, 17% at dinner and 1% at lunch. Over 
90% used pen devices, split equally between disposable (46%) and reusable devices 
(45%). Demographic and clinical characteristics, including macrovascular disease and 
cardiovascular risk proﬁles, were broadly similar between the basal insulin subgroup 
and the overall group of participants (basal insulin subgroup vs total population: 
males, 48 vs 51%; age, 62 o 11 vs 61 o 10 years; T2DM duration, 10 o 7 vs 11 o 8 
years; HbA1c, 9.2 o 1.8 vs 9.5 o 2.0%; prior use of oral glucose lowering drugs 
[OGLDs], 97 vs 93%). Use of OGLDs with insulin tended to be higher in the basal 
insulin subgroup than in the total population (any OGLD, 89 vs. 70%; biguanides, 
64 vs. 50%, sulfonylureas, 63 vs. 43%). CONCLUSIONS: The one notable difference 
between the groups was that those beginning basal insulin alone were more heavily 
treated with OGLDs beforehand than in the overall population, most commonly bigu-
anides and sulfonylureas. This suggests that they required no lesser intensity of gly-
caemic management than people starting on other types of insulin.
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OBJECTIVES: The 2008/09 Quality and Outcomes Framework (QOF) indicators for 
measuring glycosylated haemoglobin (HbA1c) levels are DM20 and DM07, which 
measure percentage of diabetic patients with HbA1c of either 7.5 or less or 10 or less 
respectively. New QOF clinical indicators have been agreed for 2009/10: DM23 
